1-bromo-8-(trideuteromethyl)naphthalene | 1037295-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-bromo-8-(trideuteromethyl)naphthalene
• 英文别名: 1-bromo-8-(methyl-d₃)naphthalene；1-Bromo-8-(trideuteriomethyl)naphthalene；1-bromo-8-(trideuteriomethyl)naphthalene
• CAS: 1037295-00-3
• 化学式: C₁₁H₉Br
• 分子量: 224.073
• InChiKey: QTWVRVGVJURUFK-FIBGUPNXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.91
• 重原子数：
  12.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为反应物：
  描述：

  1-bromo-8-(trideuteromethyl)naphthalene 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 氢气 、 caesium carbonate 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 2-((S)-4-(7-(8-(methyl-d₃)naphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile
  参考文献：
  名称：

  NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF

  摘要：

  The present invention belongs to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor, a preparation method and use thereof. In particular, the present invention provides a compound of formula I, which can be used as a high-efficiency KRAS G12C protein inhibitor and has various pharmacological activities against tumors, proliferative diseases, inflammation, autoimmune diseases, etc.

  公开号：

  US20230257374A1
• 作为产物：
  描述：

  1,8-二溴萘 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 正丁基锂 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 为溶剂， 反应 3.58h， 生成 1-bromo-8-(trideuteromethyl)naphthalene
  参考文献：
  名称：

  NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF

  摘要：

  The present invention belongs to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor, a preparation method and use thereof. In particular, the present invention provides a compound of formula I, which can be used as a high-efficiency KRAS G12C protein inhibitor and has various pharmacological activities against tumors, proliferative diseases, inflammation, autoimmune diseases, etc.

  公开号：

  US20230257374A1

文献信息

• [EN] NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF<br/>[FR] NOUVEL INHIBITEUR DE LA PROTÉINE KRAS G12C, PROCÉDÉ DE PRÉPARATION ASSOCIÉ ET UTILISATION CORRESPONDANTE<br/>[ZH] 新颖的KRAS G12C蛋白抑制剂及其制备方法和用途
  申请人：INNOVENT BIOLOGICS SUZHOU CO LTD

  公开号：WO2021068898A1

  公开（公告）日：2021-04-15

  属于药物化学领域，涉及新颖的KRAS G12C蛋白抑制剂及其制备方法和用途。具体而言，提供了一种具有式（I）结构的化合物，其可以作为高效的KRAS G12C蛋白抑制剂，具有抗肿瘤、抗增生性疾病、抗炎、抗自身免疫性疾病等多种药理活性。
• Benzylic C–H activation and C–O bond formation via aryl to benzylic 1,4-palladium migrations
  作者：Tanay Kesharwani、Richard C. Larock

  DOI：10.1016/j.tet.2008.01.144

  日期：2008.6

  A procedure for benzylic C-H activation has been developed using a palladium 1,4-aryl to benzylic migration as a key step. Carboxylates and phenoxides readily trap the resulting benzylic palladium intermediates obtained from palladium 'through space' migration. Aryl bromides and iodides have been successfully employed in this reaction, furnishing moderate to good yields. The mechanism of this reaction has been studied by deuterium-labeling experiments, which suggest that the migration of palladium from an aryl to a benzylic position occurs reversibly. The reaction conditions developed for the migration process also oxidize the neighboring benzylic alcohols to the corresponding aldehydes and ketones. (C) 2008 Elsevier Ltd. All rights reserved.